Avidity Biosciences (NASDAQ:RNA) reported quarterly losses of $(0.65) per share which beat the analyst consensus estimate of $(0.73) by 10.96 percent. This is a 8.45 percent increase over losses of $(0.71) per share from the same period last year. The company reported quarterly sales of $2.34 million which missed the analyst consensus estimate of $4.27 million by 45.29 percent. This is a 17.10 percent decrease over sales of $2.82 million the same period last year.